The current front-line pharmacological treatment for hERG-related SQTS patients is the class Ia anti-arrhythmic drug quinidine (Gaita et al., 2004; Hu et al., 2017) – a multi-channel blocker which exerts a mild blocking effect on IKs. This evidence concerns the gene KCNH2 and Familial short QT syndrome.